T hree months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from first use more than a third have stopped ...
GLP-1 drugs such as Wegovy, Ozempic, and Zepbound are a class of medications primarily taken to treat Type 2 diabetes and, more recently, obesity. Research indicates many people taking GLP-1s for ...
Ozempic, Wegovy and other GLP-1 medications could help extremely obese patients drop enough pounds to be eligible for ...
Demand for Wegovy and other GLP-1 drugs used to treat obesity and diabetes has skyrocketed, but a new report suggests that many people may not be sticking with their weight-loss treatment long enough.
Blue Cross Blue Shield of Michigan is one such insurer. Beginning in January 2025, around 10,000 people in the state will ...
New research finds that metabolic and bariatric surgery is more effective for long-term weight loss than lifestyle changes ...
These are the most common side effects and changes you may experience in the days and weeks after you stop taking GLP-1 drugs ...
Thousands of people in Michigan who use popular weight loss drugs will soon lose their coverage for it. Blue Cross Blue ...
Blue Cross Blue Shield of Michigan will drop coverage GLP-1 obesity drugs in fully insured large group commercial plans ...
Weight-loss drugs from Novo Nordisk A/S and Eli Lilly and Co. will lose coverage under many plans run by Michigan’s largest ...
Blue Cross Blue Shield of Michigan reportedly plans to drop coverage of GLP-1 obesity drugs for certain plans due to concerns ...